RxDoctor Payments Data

Adnan Arif, MD

Psychiatry · Romeoville, ILNPI 1710914890

Payments from drug & device makers

$2,832in general payments, 2019–2025

Across 50 payments — averaging $56.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Brainsway USA Inc$2K
  • Sunovion Pharmaceuticals Inc.$350
  • Johnson & Johnson$232
  • AbbVie$172
  • Neuronetics, Inc.$129
  • Alkermes, Inc.$105
  • plus $200 from 4 others

What the payments were for

  • Food & beverage$2,832100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,832 in reported general payments places this provider in the 85th percentile of 1,344 psychiatry providers in Illinois.

See all psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$56,756
Medicare patients
100
Services billed
470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide13$6,251
Aripiprazole29$3,273
Bupropion XlBupropion Hcl58$1,235
Mirtazapine38$971
Venlafaxine Hcl ErVenlafaxine Hcl50$856
Clonazepam51$750
Bupropion Hcl26$608
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine20$556
Trazodone Hcl115$506
Fluoxetine Hcl54$499
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$495
Quetiapine Fumarate43$389
Risperidone37$377
Bupropion Hcl SrBupropion Hcl36$347
Escitalopram Oxalate46$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$58$6,25113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,344 psychiatry providers in Illinois.

Other psychiatry in Romeoville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →